07:37 AM EDT, 08/01/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Friday its Visirna Therapeutics unit has signed an asset purchase agreement with Sanofi ( SNY ) for the Greater China rights to the investigational cardiometabolic drug, plozarisan.

Under the deal, Sanofi ( SNY ) will pay $130 million upfront, with up to $265 million in additional milestone payments.

The company said it is also eligible to receive royalties on net commercial product sales in Greater China under its existing license agreement, which is partly assigned to Sanofi ( SNY ).

Visirna completed a Phase 3 trial of plozasiran in China for familial chylomicronemia syndrome and submitted a marketing application in January.